Shots:

• Nimble to receive up front- milestones & royalties on sales of the therapies developed under the collaboration. The collaboration will accelerate the discovery of novel therapies targeting multiple diseases
• The agreement will utilize Nimble’s peptide synthesis- screening & optimization platform- chemical diversity- and integrated suite of assays enabling the discovery & optimization of compounds for intracellular and extracellular targets
• The collaboration will merge the strength of both the companies to offer new therapies to the patients

Click here ­to­ read full press release/ article | Ref: FDA | Image: Life Science PR Review